Borges David J. sold $85K of OMER

Borges David J. (VP, Finance & CAO) sold 5,000 shares of OMEROS CORP (OMER) at $16.95 on 2026-08-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Borges David J.
Published Aug 17, 2026, 11:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 11:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMER
Neutral
high confidence
Mentioned
$OMER
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERNeutralLow
01

Why it matters

The disclosed event is an open-market sale by an officer under a pre-arranged 10b5-1 plan, which typically has limited informational content about near-term fundamentals.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a fundamental repricing without accompanying company news.

03

What to watch

The article provides no context on total insider holdings beyond the post-transaction 0 shares, and it does not indicate whether other insiders sold or whether there were concurrent company-specific catalysts.

Relevance 2/10Novelty 2/10Timing: Form 4 filed 2026-08-17 for a sale dated 2026-08-13

Background

The article is an SEC Form 4 insider transaction disclosure for OMEROS CORP.

Company-level read

Ticker impact

$OMERNeutralHigh confidence
Context

OMEROS CORP disclosed an insider open-market sale by VP, Finance & CAO Borges David J. of 5,000 shares at $16.95 on 2026-08-13.

Expected impact

Likely limited near-term impact; any effect is typically sentiment-only and outweighed by the pre-arranged nature.

Evidence & confidence

The filing specifies a pre-arranged Rule 10b5-1 plan and an open-market sale, which generally reduces interpretive signal versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, some traders may still view insider selling as a mild negative signal, especially if it coincides with other bearish developments not mentioned here.

Key entities

  • OMEROS CORP

    Company subject of the Form 4 insider transaction disclosure.

  • Borges David J.

    VP, Finance & CAO who sold 5,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMERMed

OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares

Omeros (OMER) shares are down, heading for their worst day in 18 months. The company delayed Q4 and 2027 sales guidance, citing uncertainty. A clinical trial for OMS527 was postponed to 2027 due to delays in acquiring study animals. Despite this, retail sentiment on Stocktwits turned bullish, focusing on Yartemlea's launch and a partnership with Novo Nordisk. OMER stock is down 22% year-to-date.

$OMERMed

Omeros (OMER) Q3 2026 Earnings Call Transcript

Omeros (OMER) reported Q3 2026 earnings with YARTEMLEA generating $35.9M in net sales, up 26% from Q2. GAAP net loss was $57.4M, but non-GAAP net income was $4.7M. The company reduced convertible notes and repurchased shares. YARTEMLEA saw increased adoption and reimbursement advantages.

$OMERMed

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.

$OMERMedAI 8/10

Omeros falls 10% despite revenue beat

Omeros (NASDAQ:OMER) reported Q3 revenue of $41.8M, beating estimates, but shares fell 10% due to a widened GAAP net loss of $57.4M. Adjusted earnings were $0.06 per share, exceeding expectations. YARTEMLEA sales grew 30% sequentially. The company held $95.3M in cash as of Q3 2026.

$OMERMed

Omeros Corporation Reports Third Quarter 2026 Financial Results

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Third Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 16, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third q